Δ9-THC drug
Evidence from:
primary |
all sources
Related entities (61)
Mentioned in (29)
Papers in which this entity is mentioned.
- Gene-alcohol interactions in birth defects. (2023)
- Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling. (2020)
- Cannabinoids Exacerbate Alcohol Teratogenesis by a CB1-Hedgehog Interaction. (2019)
- A review on neuroimaging studies of genetic and environmental influences on early brain development. (2019)
- Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. (2019)
- The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. (2018)
- An Update on Non-CB, Non-CB Cannabinoid Related G-Protein-Coupled Receptors. (2017)
- The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study. (2017)
- Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. (2016)
- Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice. (2016)
- Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. (2015)
- Genome-Wide DNA Methylation Profiling Reveals Epigenetic Changes in the Rat Nucleus Accumbens Associated With Cross-Generational Effects of Adolescent THC Exposure. (2015)
- Maternal smoking during pregnancy and infant stress response: test of a prenatal programming hypothesis. (2014)
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? (2014)
- Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. (2014)
- Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. (2014)
- Baths salts, spice, and related designer drugs: the science behind the headlines. (2014)
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. (2013)
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. (2012)
- Cannabinoid receptor 1 signaling in embryo neurodevelopment. (2012)
- Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. (2012)
- Transcriptional and epigenetic mechanisms of addiction. (2011)
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. (2010)
- Cannabis and psychosis/schizophrenia: human studies. (2009)
- Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. (2009)
- EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research. (2008)
- Cannabis withdrawal in the United States: results from NESARC. (2008)
- Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. (1997)
- Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. (1996)
Merged raw entities (7)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| δ9-thc | drug | 20 | 180 |
| δ9-tetrahydrocannabinol | drug | 16 | 30 |
| delta-9-thc | drug | 1 | 1 |
| cannabis extract | drug | — | — |
| primary active constituent of marijuana | drug | — | — |
| primary psychoactive constituent of marijuana | drug | — | — |
| δ9-tetrahydrocannabinoid | drug | — | — |